|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
|
28961440 |
2017 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
The pharmacophore features were then filtered by Surflex-dock study using enoyl ACP reductase from M. tuberculosis.
|
27889632 |
2017 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
The pentacyano(isoniazid)ferrate(II) compound, named IQG-607, inhibits the enzyme 2-trans-enoyl-ACP(CoA) reductase from M. tuberculosis, a key component in the FASII system.
|
29281707 |
2017 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
|
16842188 |
2006 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
The site of action of isoniazid, used in the treatment of tuberculosis for 50 years, and the consumer antimicrobial agent triclosan were revealed recently to be the enoyl-ACP reductase of the type II FAS.
|
11591436 |
2001 |
|
Ataxic cerebral palsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we have investigated the influence of the quaternary structure of 2-trans-enoyl-ACP (CoA) reductase or InhA, from Mycobacterium tuberculosis, to its flexibility.
|
31548581 |
2019 |
|
Adamantinous Craniopharyngioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we have investigated the influence of the quaternary structure of 2-trans-enoyl-ACP (CoA) reductase or InhA, from Mycobacterium tuberculosis, to its flexibility.
|
31548581 |
2019 |
|
Ataxic cerebral palsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the absence of FXN, the NFS1-ISD11-ACP (SDA) complex was reportedly inhibited by binding of recombinant ISCU.
|
30031876 |
2018 |
|
Adamantinous Craniopharyngioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the absence of FXN, the NFS1-ISD11-ACP (SDA) complex was reportedly inhibited by binding of recombinant ISCU.
|
30031876 |
2018 |
|
Ataxic cerebral palsy
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Observed crowding effects on Mycobacterium tuberculosis 2-trans-enoyl-ACP (CoA) reductase enzyme activity are not due to excluded volume only.
|
28754992 |
2017 |
|
Adamantinous Craniopharyngioma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Observed crowding effects on Mycobacterium tuberculosis 2-trans-enoyl-ACP (CoA) reductase enzyme activity are not due to excluded volume only.
|
28754992 |
2017 |
|
Ataxic cerebral palsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
|
16842188 |
2006 |
|
Adamantinous Craniopharyngioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
|
16842188 |
2006 |
|
Presenile dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Relative to white persons with dementia, African American persons with dementia were reported to have a lower preference for comfort care (81% vs. 58%) and lower rates of completion of legal ACP (89% vs. 73%).
|
31309906 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The difficulties in creating ACP rest in improving its delivery to the tumour site and it also must maintain a low toxicity profile.
|
30686254 |
2019 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that NDUFAB1 could be a novel mitochondrial target to prevent obesity and insulin resistance by enhancing mitochondrial metabolism.-Zhang, R., Hou, T., Cheng, H., Wang, X. NDUFAB1 protects against obesity and insulin resistance by enhancing mitochondrial metabolism.
|
31530015 |
2019 |
|
Dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Relative to white persons with dementia, African American persons with dementia were reported to have a lower preference for comfort care (81% vs. 58%) and lower rates of completion of legal ACP (89% vs. 73%).
|
31309906 |
2019 |
|
Presenile dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
We therefore aimed to further explore barriers and facilitators for ACP with community-dwelling people with dementia.
|
30115008 |
2018 |
|
Presenile dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
For people with dementia, it is essential to identify the right time to introduce ACP before NH admission.
|
28988561 |
2018 |
|
Dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
For people with dementia, it is essential to identify the right time to introduce ACP before NH admission.
|
28988561 |
2018 |
|
Dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
We therefore aimed to further explore barriers and facilitators for ACP with community-dwelling people with dementia.
|
30115008 |
2018 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Even though ACP is a benign tumor, treatment is challenging because of the tumor's eloquent location.
|
28414888 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
|
28645939 |
2017 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Specific disruption of the gene expressions of TNFα downstream signals TNFSF11A or NDUFAB1 in the MBH of diet-induced obese mice reverses mitochondrial elongation and reduces obesity.
|
28489068 |
2017 |
|
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Erythrocyte acid phosphatase (ACP locus 1), also known as low-molecular-weight protein tyrosine phosphatase, has previously been associated to glycemia, dyslipidemia, and obesity.
|
19570551 |
2009 |